Mark Ballow MD, FAAAAI

Mark Ballow, MD is currently a Professor in the pediatric department at the University of South Florida, and the Morsani College of Medicine at John Hopkins All Children's Hospital in St Petersburg, Florida in the Division of Allergy/Immunology. Dr. Ballow received his medical degree from the University of Chicago School of Medicine, Chicago, Illinois. He then completed an internship and residency in pediatrics at Yale-New Haven Hospital in New Haven, Connecticut, followed by a fellowship at the University of Minnesota Hospital in Minneapolis, Minnesota in clinical immunology under the mentorship of Dr. Robert Good.

After finishing his time in the Army at Walter Reed Hospital, Dr. Ballow joined the department of pediatrics at the UConn School of Medicine in Farmington, CT. From 1988 to 2012 Dr. Ballow was Chief of the Division of Allergy, Immunology and Pediatric Rheumatology at the Women and Children's Hospital of Buffalo, an affiliate hospital of SUNY Buffalo, School of Medicine and Biomedical Sciences as well as Training Program Director of the Allergy/Immunology fellowship program, and Director of the Immunobiology Laboratory. Dr. Ballow is board certified in pediatrics, allergy and immunology, and clinical laboratory immunology.

Dr. Ballow was the President (2010-2011) of the American Academy of Allergy, Asthma and Immunology (AAAAI). Dr. Ballow is also a member of the American College of Allergy, Asthma and Immunology, and the Clinical Immunology Society. He was a member of the Blood Product Advisory Committee of CBER/FDA. He currently serves on the medical advisory committee for the Immune Deficiency Foundation (IDF) and is consulting medical director for the IDF.

Dr. Ballow is on the editorial board for Journal of Allergy and Clinical Immunology: In Practice, was co-editor for Current Opinion in Allergy and Clinical Immunology between 2001-2018. Dr. Ballow is author or coauthor of more than 180 peer-reviewed papers, 50 books/book chapters or monographs, and more than 100 abstracts. He serves on the data safety monitoring boards for four pharmaceutical phase III trials. His areas of research interest are primary immune deficiency disorders and immunoglobulin (IVIG) replacement therapy and its mechanisms of action.